These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 12075853)

  • 1. The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration.
    Smith LA; Jackson MJ; Al-Barghouthy G; Jenner P
    J Neural Transm (Vienna); 2002 Feb; 109(2):123-40. PubMed ID: 12075853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.
    Kebabian JW; Britton DR; DeNinno MP; Perner R; Smith L; Jenner P; Schoenleber R; Williams M
    Eur J Pharmacol; 1992 Dec; 229(2-3):203-9. PubMed ID: 1362704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
    Pearce RK; Jackson M; Britton DR; Shiosaki K; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1999 Feb; 142(1):51-60. PubMed ID: 10102782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous dopaminergic tone and dopamine agonist action.
    Treseder SA; Smith LA; Jenner P
    Mov Disord; 2000 Sep; 15(5):804-12. PubMed ID: 11009183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.
    Löschmann PA; Smith LA; Lange KW; Jähnig P; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1992; 109(1-2):49-56. PubMed ID: 1365671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M; Fukuda T
    Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
    [No Abstract]   [Full Text] [Related]  

  • 9. Attenuation of the locomotor-sensitizing effects of the D2 dopamine agonist bromocriptine by either the D1 antagonist SCH 23390 or the D2 antagonist raclopride.
    Wise RA; Carlezon WA
    Synapse; 1994 Jul; 17(3):155-9. PubMed ID: 7974197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats.
    Bubenikova-Valesova V; Svoboda J; Horacek J; Vales K
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):873-83. PubMed ID: 19154630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
    Temlett JA; Chong PN; Oertel WH; Jenner P; Marsden CD
    Eur J Pharmacol; 1988 Nov; 156(2):197-206. PubMed ID: 2977118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset.
    Smith LA; Jackson MG; Bonhomme C; Chezaubernard C; Pearce RK; Jenner P
    Clin Neuropharmacol; 2000; 23(3):133-42. PubMed ID: 10895396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ; Shiosaki K; Britton DR
    Eur J Pharmacol; 1996 Aug; 309(1):13-20. PubMed ID: 8864687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
    Jackson MJ; Al-Barghouthy G; Pearce RK; Smith L; Hagan JJ; Jenner P
    Pharmacol Biochem Behav; 2004 Nov; 79(3):391-400. PubMed ID: 15582011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of interactions of D1-like agonists, SKF 81297, SKF 82958 and A-77636, with cocaine: locomotor activity and drug discrimination studies in rodents.
    Chausmer AL; Katz JL
    Psychopharmacology (Berl); 2002 Jan; 159(2):145-53. PubMed ID: 11862342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.
    Treseder SA; Jackson M; Jenner P
    Br J Pharmacol; 2000 Apr; 129(7):1355-64. PubMed ID: 10742291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.